Market Place
Sourcing Support
All News #Library
Biotech
Zenas Biopharma Reveals 2025 Financials And Corporate Progress
16 Mar 2026 //
GLOBENEWSWIRE
Zenas Biopharma Presents Phase 2 Obexelimab Results In Relapsing
09 Feb 2026 //
GLOBENEWSWIRE
Zenas Biopharma To Present At Guggenheim Biotech Summit 2026
04 Feb 2026 //
GLOBENEWSWIRE
Zenas Biopharma Reports Phase 3 Success For Obexelimab In IgG4-Rd
05 Jan 2026 //
GLOBENEWSWIRE
InnoCare`s Orelabrutinib Meets Primary Endpoint in Phase 2b SLE
15 Dec 2025 //
GLOBENEWSWIRE
Zenas Biopharma Reveals Q3 2025 Financials & Corporate Update
12 Nov 2025 //
GLOBENEWSWIRE
Zenas Biopharma To Present At Healthcare Investor Conferences
11 Nov 2025 //
GLOBENEWSWIRE
Zenas Autoimmune Drug Prompts 95% Drop In Lesions In MS Study
27 Oct 2025 //
GLOBENEWSWIRE
Royalty bestows Zenas with $300M for Autoimmune Approval Push
02 Sep 2025 //
FIERCE BIOTECH
Zenas Bio to Present at Guggenheim SMID Cap Biotech Conference
28 Jan 2025 //
GLOBENEWSWIRE
Zenas Completes INDIGO Trial Enrollment in IgG4-RD
12 Nov 2024 //
GLOBENEWSWIRE
Zenas BioPharma Reports Q3 2024 Financial Results & Updates
12 Nov 2024 //
GLOBENEWSWIRE
Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab
01 Aug 2023 //
GLOBENEWSWIRE
Zenas Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab
11 Jan 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.